This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 29/4/495    most recent ATVBAHA.108.180349v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dai, S. Articles by Min, W. Search for Related Content PubMed PubMed Citation Articles by Dai, S. Articles by Min, W.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:495.)
© 2009 American Heart Association, Inc.

Integrative Physiology/Experimental Medicine

Endothelial-Specific Expression of Mitochondrial Thioredoxin Promotes Ischemia-Mediated Arteriogenesis and Angiogenesis

Shengchuan Dai; Yun He; Haifeng Zhang; Luyang Yu; Ting Wan; Zhe Xu; Dennis Jones; Hong Chen; Wang Min

From the Interdepartmental Program in Vascular Biology and Therapeutics (S.D., Y.H., H.Z., L.Y., D.J., W.M.), Yale University School of Medicine, New Haven, Conn; State Key Laboratory of Ophthalmology (T.W., Z.X.), Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China; and the Oklahoma Medical Research Foundation (H.C.), 825 NE 13th Street, Oklahoma City.

Correspondence to Dr Wang Min, Interdepartmental Program in Vascular Biology and Therapeutics, Department of Pathology, Yale University School of Medicine, 10 Amistad St, 401B, New Haven, CT 06520. E-mail wang.min{at}yale.edu

Objective— Thioredoxin-2 (Trx2), a major antioxidant protein in mitochondria, enhances nitric oxide bioavailability and inhibits ASK1-dependent apoptosis in endothelial cells (ECs). However, the in vivo role of Trx2 in angiogenesis has not been defined. Here we used EC-specific transgenesis of Trx2 (Trx2-TG) in mice to determine the in vivo function of Trx2 in arteriogenesis and angiogenesis.

Methods and Results— In a femoral artery ligation model, Trx2-TG mice had enhanced capacity in limb perfusion recovery and ischemic reserve capacity compared to the nontransgenic littermates. Ischemia-initiated arteriogenesis in the upper limb was augmented in Trx2-TG mice. Trx2-TG mice also showed significantly enhanced capillary formation and maturation in the lower limb. In nontransgenic limb, ischemia specifically induced a downregulation of Trx2 protein, leading to increased oxidative stress, ASK1 activation, and EC apoptosis. In contrast, Trx2-TG maintained a constitutive level of Trx2, reducing the ischemia-induced deleterious responses. We then defined the mechanism by which Trx2 increases angiogenesis using ECs isolated from Trx2-TG mice. Trx2-TG ECs showed increased NO and NO-dependent migration. In addition, these cells were more resistant to oxidative stress–induced activation of ASK1 signaling and apoptosis. Moreover, Trx2-augmented EC survival is NO-independent. To define the relative contributions of Trx2-increased NO and Trx2-reduced ASK1 apoptotic activity to angiogenesis in vivo, we examined Trx2 effects on ischemia-induced angiogenesis in eNOS-deficient mice. The eNOS deletion caused severe impairment in the functional flow recovery in response to ischemia. Trx2 expression in eNOS-KO mice still dramatically inhibited ischemia-induced ASK1 and EC apoptosis, leading to an enhanced functional flow recovery.

Conclusion— These in vivo and in vitro data support that Trx2 maintains EC function by two parallel pathways—scavenging ROS to increase NO bioavailability and inhibiting ASK1 activity to enhance EC survival, facilitating ischemia-mediated arteriogenesis and angiogenesis.

Key Words: thioredoxin • angiogenesis • ischemia • apoptosis